Financhill
Back

Fate Therapeutics 10K Form

Sell
34

FATE
Fate Therapeutics

Last Price:
22.62
Seasonality Move:
18.92%

7 Day Trial

ALL ACCESS PASS

$ 7

Receive FATE News And Ratings

See the #1 stock for the next 7 days that we like better than FATE

FATE Financial Statistics

Sales & Book Value

Annual Sales: $55.85M
Cash Flow: $-63.29M
Price / Cash Flow: 0
Annual Sales: $5.99
Price / Book: 3.73

Profitability

EPS (TTM): -2.64000
Net Income (TTM): $-253.72M
Gross Margin: $0
Return on Equity: -37.59%
Return on Assets: -27.66%

Fate Therapeutics Earnings Forecast

Key Fate Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 4 years for FATE is 0.00%.
  • The Selling, General & Administrative Expenses for FATE have been equal to 102.63% of Gross Profit Margin.
  • The Research & Development expenses have been 385.89% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of FATE is -379.86% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 4 years.

Fate Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: FATE
CUSIP: 31189P
Website: fatetherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.55
Quick Ratio: 6.36

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

FATE Technical Analysis vs Fundamental Analysis

Sell
34
Fate Therapeutics (FATE) is a Sell

Is Fate Therapeutics a Buy or a Sell?

  • Fate Therapeutics stock is rated a Sell
    The current Fate Therapeutics [FATE] share price is $22.34. The Score for FATE is 34, which is 32% below its historic median score of 50, and infers higher risk than normal.